Vitaxin

Vitaxin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	alpha-v beta-3 integrin
Clinical data
Trade names	Vitaxin
ATC code	none;
Identifiers
ChemSpider	none;
	(what is this?)

Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.^[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.^[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.^[3]

Vitaxin is safe for humans. It has little effect on advanced cancer.^[3]

References

↑ "New paradigms for the treatment of cancer: the role of anti-angiogenesis agents". Advances in Cancer Research (Academic Press) 79: 1–38 (27). 2000. doi:10.1016/s0065-230x(00)79001-4. ISBN 978-0-12-006679-7. PMID 10818676. https://archive.org/details/advancesincancer0000unse_f3h8/page/27.
↑ "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases 61 (Suppl 2): ii96–ii99. November 2002. doi:10.1136/ard.61.suppl_2.ii96. PMID 12379637.
↑ ^3.0 ^3.1 "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research 11 (21): 7851–7860. November 2005. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Vitaxin. Read more

[pmid10818676-1] "New paradigms for the treatment of cancer: the role of anti-angiogenesis agents". Advances in Cancer Research (Academic Press) 79: 1–38 (27). 2000. doi:10.1016/s0065-230x(00)79001-4. ISBN 978-0-12-006679-7. PMID 10818676. https://archive.org/details/advancesincancer0000unse_f3h8/page/27.

[2] "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases 61 (Suppl 2): ii96–ii99. November 2002. doi:10.1136/ard.61.suppl_2.ii96. PMID 12379637.

[522trial-3] 3.0 ^3.1 "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research 11 (21): 7851–7860. November 2005. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.

[1]

[2]

[3]

Vitaxin

Topic: Chemistry

References